Tag Archives: NYSE:SYK

Analysts Offer Insights on Healthcare Companies: Stryker Corporation (NYSE: SYK) and Nevro (NYSE: NVRO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stryker Corporation (NYSE:SYK) and Nevro (NYSE:NVRO) with bullish sentiments. Stryker Corporation (SYK) In a report released yesterday, Kyle Rose from Canaccord Genuity

RBC Capital Reiterates a Buy Rating on Stryker Corporation

In a report released today, Glenn Novarro from RBC Capital reiterated a Buy rating on Stryker Corporation (NYSE: SYK), with a price target of $184. The company’s shares closed yesterday at $172.92, close to its 52-week high of $179.84. According

Needham Maintains Their Hold Rating on Stryker Corporation

In a report released today, Michael Matson from Needham maintained a Hold rating on Stryker Corporation (NYSE: SYK). The company’s shares closed yesterday at $172.92, close to its 52-week high of $179.84. Matson noted: “SYK’s 2Q18 revenue met consensus while

BMO Capital Remains a Hold on Stryker Corporation

In a report issued on July 10, Joanne Wuensch from BMO Capital reiterated a Hold rating on Stryker Corporation (NYSE: SYK), with a price target of $174. The company’s shares closed yesterday at $173.42, close to its 52-week high of

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Stryker Corporation (NYSE: SYK), Evolus Inc (NASDAQ: EOLS) and Galmed Pharmaceuticals (NASDAQ: GLMD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stryker Corporation (NYSE: SYK), Evolus Inc (NASDAQ: EOLS) and Galmed Pharmaceuticals (NASDAQ: GLMD). Stryker Corporation (NYSE: SYK) Needham analyst Michael Matson maintained a Hold rating

Cantor Fitzgerald Remains a Hold on Stryker Corporation

Cantor Fitzgerald analyst Craig Bijou maintained a Hold rating on Stryker Corporation (NYSE: SYK) on June 11 and set a price target of $170. The company’s shares opened today at $173.23, close to its 52-week high of $179.84. Bijou observed: